Deutsche Bank Aktiengesellschaft Cuts Haleon (LON:HLN) Price Target to GBX 320

Haleon (LON:HLN) had its target price decreased by Deutsche Bank Aktiengesellschaft from GBX 335 to GBX 320 in a research report report published on Wednesday morning,Digital Look reports. Deutsche Bank Aktiengesellschaft currently has a sell rating on the stock.

Other equities analysts have also issued reports about the stock. Berenberg Bank upped their target price on shares of Haleon from GBX 512 to GBX 514 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Royal Bank Of Canada lifted their price target on Haleon from GBX 370 to GBX 390 and gave the company a “sector perform” rating in a research note on Tuesday, August 11th. Jefferies Financial Group restated a “buy” rating and issued a GBX 400 price target on shares of Haleon in a report on Friday, July 31st. Finally, JPMorgan Chase & Co. reduced their price objective on Haleon from GBX 335 to GBX 315 and set an “underweight” rating for the company in a research report on Thursday, June 25th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of GBX 387.80.

Haleon Stock Performance

Shares of HLN opened at GBX 333.80 on Wednesday. The firm has a market cap of £29.36 billion, a P/E ratio of 18.44, a PEG ratio of 1.49 and a beta of 0.24. Haleon has a twelve month low of GBX 317.80 and a twelve month high of GBX 416.10. The company has a debt-to-equity ratio of 50.38, a quick ratio of 0.93 and a current ratio of 0.69. The firm’s 50 day moving average price is GBX 362.06 and its two-hundred day moving average price is GBX 357.45.

Haleon (LON:HLN) last issued its quarterly earnings data on Thursday, July 30th. The company reported GBX 8.60 earnings per share (EPS) for the quarter. Haleon had a net margin of 14.55% and a return on equity of 9.89%. On average, analysts forecast that Haleon will post 19.5033282 EPS for the current fiscal year.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.